Immunitybio, Inc.

Rohit Duggal

Ranjeet Sinha

Patrick Soon-Shiong

Wenzhao Li

Jason Isaacson

Karl Marquez

Fereshteh Parviz

Disclosed herein are recombinant nucleic acids, comprising a 5' untranslated (5′-UTR) sequence portion, a signal peptide sequence portion, a single chain antibody fragment sequence portion, a hinge region sequence portion, a transmembrane domain sequence portion, and one or more intracellular domain sequence portions. Also disclosed herein are modified natural killer (NK) cells comprising the recombinant nucleic acid described above. Further disclosed herein are methods of treating a tumor in a subject by administering the modified NK cells.

Primary NK CAR constructs and methods

Cord blood or peripheral blood NK cells are prepared from whole blood mononuclear cells without the need to isolate CD34+ hematopoietic stem cells or NK cells, and without the need for a feeder layer. Advantageously, the methods presented herein use an enrichment process that uses antiCD16 agonist antibodies, antiCD3 antibodies, and N-803. Moreover, contemplated processes are suitable for adaptation into a fully automated production process (GMP in a box).

Mononuclear cell derived NK cells

Provided herein are methods and customized media compositions for culturing CIK NKT cells.

Growing community of inventors

San Diego, CA, United States of America

Rohit Duggal